Further contributing to the overall burden is a lack of recognition of the signs and symptoms of narcolepsy and an absence of easily measurable biomarkers, resulting in a diagnostic delay that often exceeds 10 years and may be associated with misdiagnosis and inappropriate resource utilization.
The annual direct medical costs are approximately 2-fold higher in patients with narcolepsy than in matched controls without this condition ($11,702 vs $5261, respectively P <.0001).
#NARCOLEPSY WITHOUT CATAPLEXY TREATMENT FULL#
OBJECTIVES: To provide an enhanced understanding of narcolepsy and establish the need for early diagnosis and rapid initiation of effective treatment for patients with narcolepsy.ĭISCUSSION: Narcolepsy reduces daily functioning and is associated with a substantial medical and economic burden, with many patients being on full disability. Narcolepsy is believed to be an autoimmune disorder with destruction of hypocretin-producing neurons in the lateral hypothalamus. The prevalence of narcolepsy is approximately 0.05%, and onset generally occurs during the first 2 decades of life. BACKGROUND: The neurologic disorder narcolepsy results from dysregulation of the sleep-wake cycle and is primarily characterized by chronic, severely excessive daytime sleepiness and cataplexy, an emotionally induced muscle weakness.
0 kommentar(er)
